137 |
Late Loss Remains the Best Single Indicator of DES Performance |
Richard E. Kuntz |
May. 27. 05 |
136 |
Is the TAXUS Stent Benefit Extended to the Most Complicated Patients and Lesions? |
Eberhard Grube |
May. 27. 05 |
135 |
New Drug Eluting Stents |
Alexandre Abizaid |
May. 20. 05 |
134 |
Are All Sirolimus Analogs Alike? |
Robert Falotico |
May. 20. 05 |
133 |
Paclitaxel-Eluting TAXUS Stents Strengths and Weaknesses |
Gregg W. Stone |
May. 13. 05 |
132 |
The "Appropriate" Use of IVUS During DES Procedures |
Gary S. Mintz |
May. 13. 05 |
131 |
New Diagnostic Catheter in TRI Application - Restructure Diagnosis, More Cost Efficiency and More |
Seong Man Kim |
Mar. 18. 05 |
130 |
New Technique of Guiding Catheter-5 in 6Fr - Improve Device Success during Delivery of Stent |
Yoshifumi Kan |
Mar. 18. 05 |
129 |
Real-world Indications of Bare Stent - We Still Need Bare Stent? |
Teguh Santoso |
Mar. 18. 05 |
128 |
Small Vessel Stenting - Controversy between DES and BMS |
Gian Battista Danzi |
Mar. 18. 05 |